

Webcast Alert: Transgenomic, Inc. Announces Fourth Quarter 2009 Earnings Release Conference Call Webcast

OMAHA, Neb., February 18, 2010 /PRNewswire-First Call/ -- Transgenomic, Inc. (OTC BB: [TBIO.OB](#)) announces the following Webcast:

What: Transgenomic, Inc. Fourth Quarter 2009 Earnings Release Conference Call

When: Wednesday, February 24, 2010 @ 5:00 p.m. Eastern

Where: <http://www.transgenomic.com/events.asp?id=6>

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Investor Relations, 402-452-5400

To access the call via telephone, call 800-862-9098 or 785-424-1051. A replay of the call will be available via telephone until 11:59 pm ET on Wednesday, March 10, 2010. To access, dial 800-374-0328 or 402-220-0663.

About Transgenomic, Inc.

Transgenomic, Inc. (OTC BB: TBIO.OB, www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE[®] Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR[®] Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared to manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for pharmacogenomic, translational research and clinical trials.